Xuanzhu Biology Plans Hong Kong IPO, Receives CSRC Filing Notice

Deep News

Sep 01

On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and domestic unlisted shares "full circulation" (Notice No. Guo He Han [2025] 1470).

According to the filing notice, Xuanzhu Biology plans to issue no more than 77.4335 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange. Additionally, 17 shareholders plan to convert a total of 93.368496 million domestic unlisted shares they hold into overseas listed shares.

Xuanzhu Biology submitted prospectuses to the Hong Kong Stock Exchange twice on November 25, 2024 and June 13, 2025, with CICC and CMB International serving as joint sponsors.

Xuanzhu Biology is headquartered in Beijing, registered in Shijiazhuang, Hebei, and was spun off from SIHUAN PHARM (00460.HK). As an innovation-driven Chinese biopharmaceutical company with global vision, the company has established a comprehensive internal R&D platform to support the development of a highly competitive and balanced pipeline.

As of the last practicable date, Xuanzhu Biology has more than ten drug assets under active development, covering digestive system diseases, tumors and non-alcoholic steatohepatitis (NASH). These include two NDA approved assets, two drug projects in NDA registration stage, four drug projects in Phase I clinical trial stage, and five with IND approval.

Xuanzhu Biology prospectus link: https://www1.hkexnews.hk/app/sehk/2025/107438/documents/sehk25061301829_c.pdf

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1161323446"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161323446\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161323446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161323446","market":"other","top_or_hot":-1,"title":"Xuanzhu Biology Plans Hong Kong IPO, Receives CSRC Filing Notice","media":"Deep News","content":"<p>On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and domestic unlisted shares \"full circulation\" (Notice No. Guo He Han [2025] 1470).</p>\n<p>According to the filing notice, Xuanzhu Biology plans to issue no more than 77.4335 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange. Additionally, 17 shareholders plan to convert a total of 93.368496 million domestic unlisted shares they hold into overseas listed shares.</p>\n<p>Xuanzhu Biology submitted prospectuses to the Hong Kong Stock Exchange twice on November 25, 2024 and June 13, 2025, with CICC and CMB International serving as joint sponsors.</p>\n<p>Xuanzhu Biology is headquartered in Beijing, registered in Shijiazhuang, Hebei, and was spun off from SIHUAN PHARM (00460.HK). As an innovation-driven Chinese biopharmaceutical company with global vision, the company has established a comprehensive internal R&D platform to support the development of a highly competitive and balanced pipeline.</p>\n<p>As of the last practicable date, Xuanzhu Biology has more than ten drug assets under active development, covering digestive system diseases, tumors and non-alcoholic steatohepatitis (NASH). These include two NDA approved assets, two drug projects in NDA registration stage, four drug projects in Phase I clinical trial stage, and five with IND approval.</p>\n<p>Xuanzhu Biology prospectus link:\nhttps://www1.hkexnews.hk/app/sehk/2025/107438/documents/sehk25061301829_c.pdf</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biology Plans Hong Kong IPO, Receives CSRC Filing Notice</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biology Plans Hong Kong IPO, Receives CSRC Filing Notice\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-01 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and domestic unlisted shares \"full circulation\" (Notice No. Guo He Han [2025] 1470).</p>\n<p>According to the filing notice, Xuanzhu Biology plans to issue no more than 77.4335 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange. Additionally, 17 shareholders plan to convert a total of 93.368496 million domestic unlisted shares they hold into overseas listed shares.</p>\n<p>Xuanzhu Biology submitted prospectuses to the Hong Kong Stock Exchange twice on November 25, 2024 and June 13, 2025, with CICC and CMB International serving as joint sponsors.</p>\n<p>Xuanzhu Biology is headquartered in Beijing, registered in Shijiazhuang, Hebei, and was spun off from SIHUAN PHARM (00460.HK). As an innovation-driven Chinese biopharmaceutical company with global vision, the company has established a comprehensive internal R&D platform to support the development of a highly competitive and balanced pipeline.</p>\n<p>As of the last practicable date, Xuanzhu Biology has more than ten drug assets under active development, covering digestive system diseases, tumors and non-alcoholic steatohepatitis (NASH). These include two NDA approved assets, two drug projects in NDA registration stage, four drug projects in Phase I clinical trial stage, and five with IND approval.</p>\n<p>Xuanzhu Biology prospectus link:\nhttps://www1.hkexnews.hk/app/sehk/2025/107438/documents/sehk25061301829_c.pdf</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"","article_id":"1161323446","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161323446","pubTimestamp":1756704630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1600":"工业大麻","BK1191":"制药","00460":"四环医药","BK1515":"抗疫概念","BK1593":"医美概念股"},"translate_title":"轩竹生物筹划香港IPO获证监会备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and domestic unlisted shares \"full circulation\" (Notice No. Guo He Han [2025] 1470).\nAccording to the filing notice, Xuanzhu Biology plans to issue no more than 77.4335 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange. Additionally, 17 shareholders plan to convert a total of 93.368496 million domestic unlisted shares they hold into overseas listed shares.\nXuanzhu Biology submitted prospectuses to the Hong Kong Stock Exchange twice on November 25, 2024 and June 13, 2025, with CICC and CMB International serving as joint sponsors.\nXuanzhu Biology is headquartered in Beijing, registered in Shijiazhuang, Hebei, and was spun off from SIHUAN PHARM (00460.HK). As an innovation-driven Chinese biopharmaceutical company with global vision, the company has established a comprehensive internal R&D platform to support the development of a highly competitive and balanced pipeline.\nAs of the last practicable date, Xuanzhu Biology has more than ten drug assets under active development, covering digestive system diseases, tumors and non-alcoholic steatohepatitis (NASH). These include two NDA approved assets, two drug projects in NDA registration stage, four drug projects in Phase I clinical trial stage, and five with IND approval.\nXuanzhu Biology prospectus link:\nhttps://www1.hkexnews.hk/app/sehk/2025/107438/documents/sehk25061301829_c.pdf","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}